Evidence mapPaperPMID 40926609Full record

ArticleCurrent drug discovery technologies2026

Bioactive Furan Derivatives from

Madhuri Mukindrao Moon, John Godwin Christopher

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug discovery technologies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Madhuri Mukindrao MoonSchool of Bio Sciences and Technology, Vellore Institute of Technology, VIT University, Vellore, Tamil Nadu, India.ORCID 0009-0004-1854-6957
John Godwin ChristopherSchool of Bio Sciences and Technology, Vellore Institute of Technology, VIT University, Vellore, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction

methodsStreptomyces sp. VITGV100 was grown in a nutrient broth supplemented with Magnesium and Iron elicitors. The secondary metabolites were analyzed for antioxidant activity via 2,2-diphenyl- 1-picrylhydrazyl radical scavenging activity, antimicrobial activity against

resultsMagnesium and Iron supplementation elevated the production of metabolites with antioxidant activity (90% scavenging, IC50 value 0.025 mg/ml) at 6 mg/ml of Magnesium, and antimicrobial properties show the highest inhibition zone of 23 mm against DISCUSSION: Magnesium and iron elicitation in Streptomyces sp. VITGV100 significantly enhances its antioxidant and antibacterial capabilities. Strong bioactivity and

conclusionMagnesium and Iron significantly improve the synthesis of bioactive compounds in Streptomyces sp. VITGV100, showing strong antioxidant and antimicrobial activities of these metabolites, combined with promising docking and ADMET profiles, shows promising therapeutic potential.

Indexed as

Anti-Bacterial AgentsAntioxidantsFuransStreptomycesBacillus subtilisEscherichia coliIronMagnesiumMicrobial Sensitivity TestsMolecular Docking SimulationAnti-Bacterial AgentsAntioxidantsFuransIronMagnesiumADMET analysisantimicrobial assayantioxidant assayfuran-derivativesmolecular dockingStreptomyces sp. VITGV100

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.